glp-1 obesity drug news today sep 30 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio The GLP-1 Revolution Continues

Researchers are working to understand the effects of these popular new therapies on ocular structures.

Insurers find themselves in the position of needing to say "yes" or "no" to GLP-1 drugs as more people seek them for weight loss

This advanced format helps the body better absorb and utilize Berberine HCl, paired with Ceylon Cinnamon for a well-rounded formula

semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m2 (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m2 (3.3, 6.2)

GLP-1 drugs like Ozempic and Mounjaro may offer real benefits for people with type 1 diabetes: less insulin, flatter CGM curves, and emerging evidence for heart and kidney protection.

In this study we investigated the target occupancy of the dual agonist SAR425899 at the GLP1R in pancreas and GCGR in liver by Positron Emission Tomography/Computed Tomography (PET/CT)